All In MedTech

Device Trial Radar · NCT06649097

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

Last checked: Nov 19, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Sep 25, 2025

Primary completion

Jan 2031

Study completion Jul 2031

Sponsor

Lead sponsor
Christopher P KellnerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
IRRAS
First posted
Oct 18, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.

Conditions

  • Intracranial Hemorrhage
  • Ventriculitis
  • Intracranial Abscess

Interventions

  • IRRAflow® CNS (Active Fluid Exchange) SystemDevice

    The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Residual blood volume by post bleed day 5Time frame: Post-procedure day 5
  2. Utility weighted modified Rankin ScoreTime frame: End of study, at 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.